KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Operations (2016 - 2025)

Regeneron Pharmaceuticals has reported Cash from Operations over the past 17 years, most recently at 1170700000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 1170700000.0 for Q4 2025, down 7.29% from a year ago — trailing twelve months through Dec 2025 was 4978900000.0 (up 12.63% YoY), and the annual figure for FY2025 was 4978900000.0, up 12.63%.
  • Cash from Operations for Q4 2025 was 1170700000.0 at Regeneron Pharmaceuticals, down from 1618700000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for REGN hit a ceiling of 3413600000.0 in Q3 2021 and a floor of 354000000.0 in Q2 2024.
  • Median Cash from Operations over the past 5 years was 1157550000.0 (2025), compared with a mean of 1304480000.0.
  • Biggest five-year swings in Cash from Operations: surged 1442.35% in 2021 and later tumbled 81.58% in 2022.
  • Regeneron Pharmaceuticals' Cash from Operations stood at 2372500000.0 in 2021, then decreased by 27.51% to 1719900000.0 in 2022, then tumbled by 36.64% to 1089700000.0 in 2023, then increased by 15.89% to 1262800000.0 in 2024, then decreased by 7.29% to 1170700000.0 in 2025.
  • The last three reported values for Cash from Operations were 1170700000.0 (Q4 2025), 1618700000.0 (Q3 2025), and 1144400000.0 (Q2 2025) per Business Quant data.